GSK Expands Its Asthma and COPD Portfolio in the US – Pharmaceutical Processing


SYS-CON Media

GSK Expands Its Asthma and COPD Portfolio in the US
Pharmaceutical Processing
GlaxoSmithKline has announced the simultaneous availability of two of its recently approved products for the treatment of asthma and COPD to retail pharmacies in the US. Over the past 15 months, GSK has launched four inhaled respiratory therapies in
GSK Expands Its Portfolio Of Medicines In US To Treat Asthma And COPDRTT News
GSK expands its portfolio of medicines in the US for patients with asthma and MarketWatch

all 4 news articles »

View full post on asthma – Google News

Nearly Half of Older Adults With Asthma, COPD Still Smoke: CDC – U.S. News & World Report

Nearly Half of Older Adults With Asthma, COPD Still Smoke: CDC
U.S. News & World Report
WEDNESDAY, Jan. 7, 2015 (HealthDay News) — Close to half of U.S. adults over 40 who have trouble breathing due to asthma or COPD still continue to smoke, federal health officials reported Wednesday. The findings highlight the difficulty facing many …
About 1 in 7 Older Adults Has Some Form of Lung Disease: CDCDoctors Lounge
US Lung Obstruction Rates Steady at About 15%Medscape

all 7 news articles »

View full post on asthma – Google News

Britain’s Vectura collaborates with Janssen in asthma, COPD – Yahoo News

Britain's Vectura collaborates with Janssen in asthma, COPD
Yahoo News
LONDON (Reuters) – Vectura Group, a respiratory drugs specialist, will work with Janssen Biotech to develop treatments for asthma and lung disease COPD, it said on Tuesday. The collaboration will kick off with the development of a drug candidate for …
Vectura Signs Global Development And Licence Deal With Janssen In Asthma RTT News
Vectura links with Janssen on asthma/COPD drug developmentThe Pharma Letter
J&J and Vectura sign asthma/COPD dealPharmaTimes
London South East
all 10 news articles »

View full post on asthma – Google News

Britain’s Vectura collaborates with Janssen in asthma, COPD – Reuters

Britain's Vectura collaborates with Janssen in asthma, COPD
Reuters
Janssen, a unit of Johnson & Johnson, will then use Vectura's dry powder inhaler technologies in the development of inhaled therapeutics for airways-related diseases such as asthma, a market worth in excess of $46 billion worldwide, Vectura said
Vectura Signs Global Development And Licence Deal With Janssen In Asthma RTT News
Vectura links with Janssen on asthma/COPD drug developmentThe Pharma Letter
Vectura In Deal With Johnson & Johnson's Janssen Biotech For AsthmaLondon South East
Business Weekly
all 6 news articles »

View full post on asthma – Google News